Medicina Clinica最新文献

筛选
英文 中文
Colangiocarcinoma intrahepático en un paciente con colangitis biliar primaria 原发性胆管炎患者的肝内血管癌
IF 2.6 4区 医学
Medicina Clinica Pub Date : 2025-05-24 DOI: 10.1016/j.medcli.2025.107006
Pablo Fernández Rodríguez , Rosario Serrano Pardo , Luisa Consuelo García Buey
{"title":"Colangiocarcinoma intrahepático en un paciente con colangitis biliar primaria","authors":"Pablo Fernández Rodríguez , Rosario Serrano Pardo , Luisa Consuelo García Buey","doi":"10.1016/j.medcli.2025.107006","DOIUrl":"10.1016/j.medcli.2025.107006","url":null,"abstract":"","PeriodicalId":18578,"journal":{"name":"Medicina Clinica","volume":"165 2","pages":"Article 107006"},"PeriodicalIF":2.6,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144123932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rapid response to anifrolumab in refractory systemic lupus erythematosus 对难治性系统性红斑狼疮的快速反应
IF 2.6 4区 医学
Medicina Clinica Pub Date : 2025-05-24 DOI: 10.1016/j.medcli.2025.107007
Diego López-Martínez , Nuria Lozano-Rivas , Paloma Sánchez-Pedreño-Guillen
{"title":"Rapid response to anifrolumab in refractory systemic lupus erythematosus","authors":"Diego López-Martínez , Nuria Lozano-Rivas , Paloma Sánchez-Pedreño-Guillen","doi":"10.1016/j.medcli.2025.107007","DOIUrl":"10.1016/j.medcli.2025.107007","url":null,"abstract":"","PeriodicalId":18578,"journal":{"name":"Medicina Clinica","volume":"165 3","pages":"Article 107007"},"PeriodicalIF":2.6,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144125167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mixed autoimmune haemolytic anaemia in a patient with Hashimoto's thyroiditis and sarcoidosis 桥本甲状腺炎合并结节病合并自身免疫性溶血性贫血1例
IF 2.6 4区 医学
Medicina Clinica Pub Date : 2025-05-23 DOI: 10.1016/j.medcli.2025.106979
Isidora Rubezic Lukic , Vesko Vujicic , Enisa Zaric
{"title":"Mixed autoimmune haemolytic anaemia in a patient with Hashimoto's thyroiditis and sarcoidosis","authors":"Isidora Rubezic Lukic , Vesko Vujicic , Enisa Zaric","doi":"10.1016/j.medcli.2025.106979","DOIUrl":"10.1016/j.medcli.2025.106979","url":null,"abstract":"","PeriodicalId":18578,"journal":{"name":"Medicina Clinica","volume":"165 1","pages":"Article 106979"},"PeriodicalIF":2.6,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144116872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Body packer 身体封隔器
IF 2.6 4区 医学
Medicina Clinica Pub Date : 2025-05-23 DOI: 10.1016/j.medcli.2025.106970
Mehmet Tonkaz, Duygu Erkal, Gökhan Tonkaz
{"title":"Body packer","authors":"Mehmet Tonkaz, Duygu Erkal, Gökhan Tonkaz","doi":"10.1016/j.medcli.2025.106970","DOIUrl":"10.1016/j.medcli.2025.106970","url":null,"abstract":"","PeriodicalId":18578,"journal":{"name":"Medicina Clinica","volume":"165 3","pages":"Article 106970"},"PeriodicalIF":2.6,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144115883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictive value of bicarbonate levels at admission for severe hypoxic-ischemic encephalopathy after out-of-hospital cardiac arrest 院外心脏骤停后重症缺氧缺血性脑病入院时碳酸氢盐水平的预测价值
IF 2.6 4区 医学
Medicina Clinica Pub Date : 2025-05-23 DOI: 10.1016/j.medcli.2025.106977
Marc Izquierdo Ribas , Teresa López-Sobrino , Eva Moreno , Oriol de Diego , Carlos Roca , Pedro Cepas , Francisco Rafael Jiménez-Trinidad , Nuria Romeu , Marta Parellada , Silvia Pérez , Xavier Freixa , José Tomás Ortiz-Pérez , Ana García-Álvarez , Rut Andrea
{"title":"Predictive value of bicarbonate levels at admission for severe hypoxic-ischemic encephalopathy after out-of-hospital cardiac arrest","authors":"Marc Izquierdo Ribas ,&nbsp;Teresa López-Sobrino ,&nbsp;Eva Moreno ,&nbsp;Oriol de Diego ,&nbsp;Carlos Roca ,&nbsp;Pedro Cepas ,&nbsp;Francisco Rafael Jiménez-Trinidad ,&nbsp;Nuria Romeu ,&nbsp;Marta Parellada ,&nbsp;Silvia Pérez ,&nbsp;Xavier Freixa ,&nbsp;José Tomás Ortiz-Pérez ,&nbsp;Ana García-Álvarez ,&nbsp;Rut Andrea","doi":"10.1016/j.medcli.2025.106977","DOIUrl":"10.1016/j.medcli.2025.106977","url":null,"abstract":"<div><h3>Introduction</h3><div>Mortality after an out-of-hospital cardiac arrest (OHCA) remains excessively high. The use of extracorporeal cardiopulmonary resuscitation at admission may improve survival, but selecting candidates for this therapy is challenging. Finding the best predictive biomarkers of severe hypoxic-ischemic brain injury (HIBI) on arrival might aid in the multimodal decision making. Our aim was to analyse the predictive value of the acid–base balance components in this scenario.</div></div><div><h3>Methods</h3><div>This was a prospective observational study of OHCA patients that achieved return of spontaneous circulation without administration of HCO<sub>3</sub> during resuscitation, admitted to an ICCU of a tertiary care centre. Point-of-care arterial biomarkers on arrival, including pH, pCO<sub>2</sub> and HCO<sub>3</sub> were analysed. The primary objective was severe HIBI.</div></div><div><h3>Results</h3><div>From 2019 to 2021, 50 OHCA patients were included, of which 17 (34%) suffered severe HIBI. Initial pH (6.99<!--> <!-->±<!--> <!-->0.20 vs. 7.14<!--> <!-->±<!--> <!-->0.15, <em>P</em> <!-->=<!--> <!-->0.007) and HCO<sub>3</sub> values (14.13<!--> <!-->±<!--> <!-->3.24<!--> <!-->mEq/L vs. 17.97<!--> <!-->±<!--> <!-->4.28<!--> <!-->mEq/L, <em>P</em> <!-->=<!--> <!-->0.003) were significantly lower in severe HIBI patients, while no difference was observed regarding pCO<sub>2</sub> (52.44<!--> <!-->±<!--> <!-->14.41<!--> <!-->mmHg vs. 51.38<!--> <!-->±<!--> <!-->13.38<!--> <!-->mmHg, <em>P</em> <!-->=<!--> <!-->0.801). HCO<sub>3</sub> showed higher accuracy to predict severe HIBI than pH (AUC of 0.764 vs. 0.727), with a value of 16.5<!--> <!-->mmol/L as the best cut-off point.</div></div><div><h3>Conclusions</h3><div>First HCO<sub>3</sub> levels on admission of OHCA patients who achieved ROSC significantly predicted severe HIBI, unlike pCO<sub>2</sub>, and showed even better accuracy than pH.</div></div>","PeriodicalId":18578,"journal":{"name":"Medicina Clinica","volume":"165 2","pages":"Article 106977"},"PeriodicalIF":2.6,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144114970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Situación pospandemia COVID-19 del número de casos y perfil de los pacientes atendidos por sospecha de violencia sexual infantil y adolescente 2019冠状病毒病大流行后的儿童和青少年性暴力疑似病例数和患者情况
IF 2.6 4区 医学
Medicina Clinica Pub Date : 2025-05-23 DOI: 10.1016/j.medcli.2025.106988
Ana I. Curcoy Barcenilla , Nerea Garcia Holguera , Carla Cano Garcia , Marta Simó Nebot , Carles Luaces Cubells , Victoria Trenchs Sainz de la Maza
{"title":"Situación pospandemia COVID-19 del número de casos y perfil de los pacientes atendidos por sospecha de violencia sexual infantil y adolescente","authors":"Ana I. Curcoy Barcenilla ,&nbsp;Nerea Garcia Holguera ,&nbsp;Carla Cano Garcia ,&nbsp;Marta Simó Nebot ,&nbsp;Carles Luaces Cubells ,&nbsp;Victoria Trenchs Sainz de la Maza","doi":"10.1016/j.medcli.2025.106988","DOIUrl":"10.1016/j.medcli.2025.106988","url":null,"abstract":"<div><h3>Background and objective</h3><div>After the pandemic, the Barcelona adult's reference centre for victims of sexual assault reported a 40% increase in its consultations. Our objective is to determine if cases of suspected child and adolescent sexual violence (CASV) also increased and if the profile of the victims changed.</div></div><div><h3>Materials and methods</h3><div>Cross-sectional study. Patients &lt;<!--> <!-->18 years of age treated for suspected CASV in 2019 and 2022 by a Functional Team of Experts were included and their characteristics were compared.</div></div><div><h3>Results</h3><div>One hundred thirty-fivecases from 2019 and 163 from 2022 were included. 83.2% were female. The mean age was 10 vs. 12 years (<em>P</em>=.064), 11.9% vs. 25.2% (<em>P</em>=.004) had a psychiatric history, and 59.3% vs. 43.6% (<em>P</em>=.039) were referred from the hospital. 0.7% sexually transmitted infections were diagnosed in 2019 vs. 4.3% in 2022 (<em>P</em>=.076). A possible aggressor was reported in 287 (96.9% male): it was a cohabitant in 47.3% vs. 28.8% (<em>P</em>=.001).</div></div><div><h3>Conclusions</h3><div>A substantial increase in cases with suspected CASV was detected; affecting more adolescent girls, more exposed to non-cohabiting aggressors, making it necessary to insist on awareness and prevention campaigns in this age group.</div></div>","PeriodicalId":18578,"journal":{"name":"Medicina Clinica","volume":"165 3","pages":"Article 106988"},"PeriodicalIF":2.6,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144115881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ventricular extrasystoles secondary to mitral valve prolapse as an initial manifestation of cardiac sarcoidosis. A case report 继发于二尖瓣脱垂的室性心动过速是心脏结节病的最初表现。病例报告
IF 2.6 4区 医学
Medicina Clinica Pub Date : 2025-05-23 DOI: 10.1016/j.medcli.2025.106976
Javier del Cid Lemus , Carlos Feijoo-Massó , Daniel Valcarcel-Paz
{"title":"Ventricular extrasystoles secondary to mitral valve prolapse as an initial manifestation of cardiac sarcoidosis. A case report","authors":"Javier del Cid Lemus ,&nbsp;Carlos Feijoo-Massó ,&nbsp;Daniel Valcarcel-Paz","doi":"10.1016/j.medcli.2025.106976","DOIUrl":"10.1016/j.medcli.2025.106976","url":null,"abstract":"","PeriodicalId":18578,"journal":{"name":"Medicina Clinica","volume":"165 1","pages":"Article 106976"},"PeriodicalIF":2.6,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144116873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of cholecalciferol on 25-hydroxyvitamin D in people living with HIV and vitamin D deficiency: A prospective observational study 胆骨化醇对艾滋病毒和维生素D缺乏症患者25-羟基维生素D的影响:一项前瞻性观察研究
IF 2.6 4区 医学
Medicina Clinica Pub Date : 2025-05-23 DOI: 10.1016/j.medcli.2025.106972
Cristina Tomás , Ángeles Muñoz , Carlos Báguena , Antonia Alcaraz , Rodrigo Martínez-Rodríguez , María Dolores Hernández , María Isabel Martínez , Rubén Corral-San-Miguel , Eduardo Pons-Fuster López , Eva García-Villalba , Salvador Valero , Eva Oliver Galera , Elena Guijarro Westermeyer , Román González Hipólito , Concepción Corbalán Dólera , María del Carmen García Ros , Enrique Bernal
{"title":"Effect of cholecalciferol on 25-hydroxyvitamin D in people living with HIV and vitamin D deficiency: A prospective observational study","authors":"Cristina Tomás ,&nbsp;Ángeles Muñoz ,&nbsp;Carlos Báguena ,&nbsp;Antonia Alcaraz ,&nbsp;Rodrigo Martínez-Rodríguez ,&nbsp;María Dolores Hernández ,&nbsp;María Isabel Martínez ,&nbsp;Rubén Corral-San-Miguel ,&nbsp;Eduardo Pons-Fuster López ,&nbsp;Eva García-Villalba ,&nbsp;Salvador Valero ,&nbsp;Eva Oliver Galera ,&nbsp;Elena Guijarro Westermeyer ,&nbsp;Román González Hipólito ,&nbsp;Concepción Corbalán Dólera ,&nbsp;María del Carmen García Ros ,&nbsp;Enrique Bernal","doi":"10.1016/j.medcli.2025.106972","DOIUrl":"10.1016/j.medcli.2025.106972","url":null,"abstract":"<div><h3>Objectives</h3><div>To assess the effect of oral cholecalciferol 50,000<!--> <!-->IU monthly administered in people living with HIV (PLHIV) and 25(OH)D deficiency followed over 48 weeks.</div></div><div><h3>Methods</h3><div>A prospective observational study was conducted in a cohort of 110 PLHIV with 25(OH)D levels<!--> <!-->&lt;<!--> <!-->20<!--> <!-->ng/mL. Changes in 25(OH)D levels were evaluated at 3, 6, and 12 months of treatment. The percentages of patients who achieved 25(OH)D levels<!--> <!-->&gt;<!--> <!-->20 and &gt;30<!--> <!-->ng/mL and changes in bone mineral density (BMD) were assessed.</div></div><div><h3>Results</h3><div>One hundred ten PLHIV (79% men, mean age 49.46 years) were included. The mean (standard deviation, SD) time on antiretroviral treatment was 10.69 (8.31) years and all patients had a viral load<!--> <!-->&lt;<!--> <!-->50<!--> <!-->copies/mL. The mean 25(OH)D levels of 15.10<!--> <!-->±<!--> <!-->3.22<!--> <!-->ng/mL at baseline increased significantly (<em>P</em> <!-->&lt;<!--> <!-->0.001) to 27.89<!--> <!-->±<!--> <!-->7.79<!--> <!-->ng/mL at 3 months, 28.53<!--> <!-->±<!--> <!-->8.45<!--> <!-->ng/mL at 6 months and 27.89<!--> <!-->±<!--> <!-->7.92<!--> <!-->ng/mL at 12 months. A total of 87.27% had normal 25(OH)D levels at 12 months (&gt;30<!--> <!-->ng/mL in 36.1% of patients and &gt;20<!--> <!-->ng/mL in 51.5%). Parathormone levels (PTH) also decreased significantly. Treatment was safe and well tolerated. On the other hand, no significant changes were observed in BMD.</div></div><div><h3>Conclusions</h3><div>Monthly administration of 50,000<!--> <!-->IU of cholecalciferol was effective in normalizing 25(OH)D deficiency in 87% of PLHIV, without observing changes in bone mineral density.</div></div>","PeriodicalId":18578,"journal":{"name":"Medicina Clinica","volume":"165 2","pages":"Article 106972"},"PeriodicalIF":2.6,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144115866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID de larga duración 长期的新型冠状病毒
IF 2.6 4区 医学
Medicina Clinica Pub Date : 2025-05-23 DOI: 10.1016/j.medcli.2025.107009
Anabel Franco-Moreno, Juan Torres-Macho
{"title":"COVID de larga duración","authors":"Anabel Franco-Moreno,&nbsp;Juan Torres-Macho","doi":"10.1016/j.medcli.2025.107009","DOIUrl":"10.1016/j.medcli.2025.107009","url":null,"abstract":"","PeriodicalId":18578,"journal":{"name":"Medicina Clinica","volume":"165 2","pages":"Article 107009"},"PeriodicalIF":2.6,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144114968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efectividad y seguridad de remdesivir y nirmatrelvir-ritonavir en la COVID-19 leve-moderada en los servicios de urgencia hospitalaria españoles 瑞德西韦和尼马崔韦-利托那韦在西班牙医院急诊科中用于轻度至中度新型冠状病毒治疗的有效性和安全性
IF 2.6 4区 医学
Medicina Clinica Pub Date : 2025-05-23 DOI: 10.1016/j.medcli.2025.106912
Cristóbal M. Rodríguez-Leal , Juan González del Castillo , Martín Sebastián Ruiz Grinspan , Rosario Susi García , Teresa Pérez Pérez , en nombre del grupo de estudio COVID CODE SPAIN
{"title":"Efectividad y seguridad de remdesivir y nirmatrelvir-ritonavir en la COVID-19 leve-moderada en los servicios de urgencia hospitalaria españoles","authors":"Cristóbal M. Rodríguez-Leal ,&nbsp;Juan González del Castillo ,&nbsp;Martín Sebastián Ruiz Grinspan ,&nbsp;Rosario Susi García ,&nbsp;Teresa Pérez Pérez ,&nbsp;en nombre del grupo de estudio COVID CODE SPAIN","doi":"10.1016/j.medcli.2025.106912","DOIUrl":"10.1016/j.medcli.2025.106912","url":null,"abstract":"<div><h3>Background and objectives</h3><div>Remdesivir and nirmatrelvir-ritonavir (NTV/r) are the antiviral drugs available in Spain to prevent progression of mild-moderate COVID-19 in vulnerable populations. The pivotal clinical trials of both were conducted under different epidemiological conditions than the current ones. Therefore, their effect in the current setting is uncertain.</div></div><div><h3>Patients and methods</h3><div>A retrospective, multicentre, observational cohort study was conducted in 16 Spanish hospital emergency departments (ED). Data were collected from all patients with mild to moderate COVID-19 who presented to an ED in the first seven days after symptom onset between 1<sup>st</sup> January and 31<sup>st</sup> August 2022. The incidence of hospitalisation or death from any cause at 30 days (composite endpoint) after discharge from the ED was assessed, as was the occurrence of serious adverse drug reactions (ADRs). Data were analysed using Cox multiple regression and standardised survival curves.</div></div><div><h3>Results</h3><div>A total of 2533 patients were included. The use of NTV/r was associated with a reduced risk of the combined endpoint compared to standard of care (SOC): adjusted hazard ratio (aHR) 0.528, 97.5% confidence interval (97.5%CI): 0.330-0.845; number of patients to treat to avoid an event, 24 (97,5%CI 13-283). No difference was detected between remdesivir and SOC: aHR 0.835: 97,5%CI: 0.524-1.394. No serious ADRs were identified.</div></div><div><h3>Conclusion</h3><div>Early use of NTV/r was associated with less risk of progression of mild to moderate COVID-19 in vulnerable patients, while no differences were found between remdesivir and SOC. Their use was safe.</div></div>","PeriodicalId":18578,"journal":{"name":"Medicina Clinica","volume":"165 2","pages":"Article 106912"},"PeriodicalIF":2.6,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144123931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信